My work focuses on identifying clinically relevant cancer specific Human Leukocyte Antigen (HLA) ligands that will guide the development of personalized cancer immunotherapy using mass-spectrometry (MS), currently the only methodology to identify unbiasedly HLA binding peptides that are presented in vivo to cytotoxic T cells. In the clinic, we aim to integrate, for the first time, mass-spectrometry-based immunopeptidomics into the innovative translational clinical strategy of personalized immunotherapy within the department of oncology.